Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Single Lung Transplant (BOSTON-2)

Bronchiolitis Obliterans Clinical Trial

— BOSTON-2  

Official title:

A Phase III Clinical Trial to Demonstrate Efficacy / Safety of Liposomal Cyclosporine A + Standard of Care (SoC) vs SoC Alone in Treating Chronic Lung Allograft Dysfunction / Bronchiolitis Obliterans in Patients Post Double Lung Transplant

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03656926
• Other study ID #: BT - L-CsA - 302 - DLT
• Secondary ID: 2018-003205-25
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: March 29, 2019
• Est. completion date: October 9, 2024

Study information

• Verified date: October 2023
• Source: Zambon SpA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objective of the trial is to assess efficacy and safety of add-on aerosolized liposomal cyclosporine A (L-CsA) to Standard of Care (SoC) therapy as compared to SoC therapy alone in the treatment of Bronchiolitis obliterans syndrome (BOS) in double lung transplant recipients.

Description:

This is a Phase III randomized, controlled clinical trial of L-CsA for the treatment of bronchiolitis obliterans syndrome in adults diagnosed with BOS following double lung transplant. Patients will receive either L-CsA (10 mg) via the PARI Investigational eFlow® Device twice daily plus Standard of Care (SoC) treatment, or SoC alone, for a period of 48 weeks. All patients will be eligible to continue in an open-label extension trial of L-CsA following completion of BOSTON-2. Regardless of treatment allocation, all patients will continue to receive their SoC regimen for maintenance of the lung allograft. Eligible patients for the clinical trial must have a tacrolimus-based triple-drug therapy in combination with mycophenolate mofetil or its equivalent and a corticosteroid. A total of 11 visits will be performed during the clinical trial. After informed consent has been obtained, a Screening Visit will be carried out in order to check general eligibility for participation. At the Randomization Visit, inclusion and exclusion criteria will be re-checked and spirometry performed. During the 48-week treatment period, visits are scheduled every 4-8 weeks. If a patient has an event that meets one of the criteria for progression of BOS, he/she will return to the clinic at least 2-weeks later for an unscheduled visit to have spirometry and other procedures performed.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 220
• Est. completion date: October 9, 2024
• Est. primary completion date: April 5, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Adult patients = 18 years who received a double lung transplant at least 12 months prior to Screening.

2. Patients with BOS diagnosis defined as CLAD-BOS phenotype with:

1. Screening FEV1 between 85-51% of personal best FEV1 value post transplant. OR

2. Screening FEV1 >85% of personal best FEV1 associated with EITHER a = 200 mL decrease in FEV1 in the previous 12 months OR according to medical history showing BOS progression.

3. Diagnosis of CLAD-BOS must be made at least 12 months after lung transplantation and

1. within 12 months prior to the screening visit OR

2. more than 12 months from screening and patient must have shown a decline in FEV1 = 200ml in the previous 12 months before screening, which is not due to acute infection or acute organ rejection

4. Patients in whom the diagnosis of BOS has been confirmed by the elimination of other possible causes of obstructive or restrictive lung disease (CLAD - RAS phenotype, see Protocol Specific Definitions).

5. Patients should be on a maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. In case a patient is also receiving concomitant azithromycin for prophylaxis or treatment of BOS, in addition to the previously described immunosuppressive regimen, azithromycin must be on a stable regimen for at least 4-weeks prior to randomization.

6. Patients capable of understanding the purposes and risks of the clinical trial, who have given written informed consent and agree to comply with the clinical trial requirements/visit schedules, and who are capable of aerosol inhalation. Patients must consent to retrieve prespecified data from the historic medical record (e.g., information related to the transplant surgery; spirometry data; medication use).

Exclusion Criteria:

1. Patients with confirmed other causes for loss of lung function, such as acute infection, acute rejection, restrictive allograft syndrome (RAS) (CLAD - RAS phenotype, see Protocol Specific Definition ), etc.

2. Cystic Fibrosis patients with multi-drug resistant infections not responding to available anti-microbial therapies.

3. Patients with acute antibody-mediated rejection at Screening. In this context, clinically stable patients (as judged by the Investigator) with detectable levels of donor specific antibodies (DSA) at the Screening Visit are eligible for the study.

4. Active acute bacterial, viral, or fungal infection not successfully resolved at least 4 weeks prior to the Screening Visit. Patients with chronic infection or colonization who are clinically stable as per judgement of the Investigator are eligible for the study.

5. Mechanical ventilation (including CPAP) within 12 weeks prior to Randomization.

6. Patients with uncontrolled hypertension.

7. Patient has baseline resting oxygen saturation of < 89% on room air or use of supplemental oxygen at rest.

8. Evidence of functional airway stenosis (e.g., bronchomalacia/tracheomalacia, airway stents, or airways requiring balloon dilatations to maintain patency) with onset after the initial diagnosis of BOS and ongoing at Screening and/or Randomization Visit.

9. Known hypersensitivity to L-CsA or to cyclosporine A.

10. Patients with chronic renal failure, defined as serum creatinine > 2.5 mg/dL at screening, or requiring chronic dialysis.

11. Patients with liver disease and serum bilirubin > 3-fold upper limit of normal range or transaminases > 2.5 upper limit of normal range.

12. Patients with active malignancy within the previous 2 years, including post-transplant lymphoproliferative disorder, with the exception of treated, localized basal and squamous cell carcinomas.

13. Pregnant women or women who are unwilling to use appropriate birth control to avoid pregnancy through their End of Study Visit.

14. Women who are currently breastfeeding.

15. Receipt of an investigational drug as part of a clinical trial within 4 weeks prior to the Screening Visit. This is defined as any treatment that is implemented under an Investigational New Drug (IND) or compassionate use.

16. Patients who have received extracorporeal photophoresis (ECP) for treatment of BOS within 1 month prior to Randomization.

17. Patients who are currently participating in an interventional clinical trial.

18. Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary procedures.

19. Any co-existing medical condition that in the Investigator's judgment will substantially increase the risk associated with the patient's participation in the clinical trial.

Related Conditions & MeSH terms

• Bronchiolitis
• Bronchiolitis Obliterans
• Bronchiolitis Obliterans Syndrome
• Chronic Lung Allograft Dysfunction
• Chronic Rejection of Lung Transplant
• Lung Transplant Failure and Rejection
• Lung Transplant Rejection
• Lung Transplant; Complications

Intervention

Drug:
• Liposomal Cyclosporine A
This formulation is developed for inhalation use and delivered via the PARI eFlow® Device, which is a new technology of nebulizing liquid drugs with a perforated vibrating membrane resulting in an aerosol with a low ballistic momentum and a high percentage of droplets in a respirable size range of 3-5 µm
• Standard of Care
Standard of Care Therapy. Eligible patients should be on a maintenance regimen of immunosuppressive agents including tacrolimus, a second agent such as but not limited to MMF or azathioprine, and a systemic corticosteroid such as prednisone as third agent. The regimen must be stable within 4 weeks prior to randomization with respect to the therapeutic agents. Patients receiving azithromycin for prophylaxis or treatment of BOS, must be on a stable regimen for a least 4-weeks prior to randomization and will continue to receive azithromycin during the trial as deemed appropriate by the investigator

Locations

Country	Name	City	State
Austria	Waehringer Guertel	Vienna
Belgium	CHU Erasme	Brussels
Belgium	Universitair Ziekenhuis Leuven	Leuven
Denmark	Copenhagen University Hospital	Copenhagen
France	CHU Hopital Nord	Marseille
France	Marie-Lannelongue	Paris
France	Hôpitaux Universitaires de Strasbourg	Strasbourg
Germany	Hannover Medical School	Hannover
Germany	LMU Klinikum Großhadern	Munich
Israel	Rabin Medical Center	Petah tikva
Spain	Hospital Universitari Vall d'Hebron	Barcelona
Spain	Complexo Hospitalario de A Coruna	Coruña
Spain	Hospital Puerta de Hierro	Madrid
Spain	Hospital Marques de Valdecilla	Santander
Spain	University Hospital LA Fe	Valencia
United Kingdom	Royal Papworth Hospital	Cambridge
United Kingdom	University of Manchester	Manchester
United States	Johns Hopkins University Hospital	Baltimore	Maryland
United States	University of Maryland	Baltimore	Maryland
United States	Cleveland Clinic	Cleveland	Ohio
United States	Ohio State University Medical Center	Columbus	Ohio
United States	Baylor University Medical Center	Dallas	Texas
United States	University of Texas Southwestern Medical Center	Dallas	Texas
United States	Duke University Medical Center	Durham	North Carolina
United States	University of Florida Medical Center	Gainesville	Florida
United States	Baylor College of Medicine	Houston	Texas
United States	Houston Methodist Hospital	Houston	Texas
United States	Indiana University	Indianapolis	Indiana
United States	Mayo Clinic Jacksonville	Jacksonville	Florida
United States	University of Kentucky Albert B. Chandler Hospital	Lexington	Kentucky
United States	UCLA Medical Center	Los Angeles	California
United States	Columbia University Medical Center	New York	New York
United States	Stanford University Hospital	Palo Alto	California
United States	Temple University Hospital	Philadelphia	Pennsylvania
United States	Banner Health	Phoenix	Arizona
United States	University of Pittsburgh Medical Center	Pittsburgh	Pennsylvania
United States	Barnes Jewish Hospital	Saint Louis	Missouri
United States	UC San Francisco	San Francisco	California
United States	University of South Florida	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
Zambon SpA

Countries where clinical trial is conducted

United States,  Austria,  Belgium,  Denmark,  France,  Germany,  Israel,  Spain,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Adverse Events	An untoward medical occurrence after exposure to a medicine, which is not necessarily caused by that medicine.	Baseline through study completion (52 weeks)
Other	Acute tolerability of L-CsA	Change in forced expiratory volume in one second (FEV1); reports of cough or shortness of breath.; Parameters reflecting acute tolerability of IMP are: spirometry, before and 1 hour and 4 hours after inhalation of L-CsA at initial dosing.; cough, or; dyspnea.	Baseline through Week 48
Primary	Mean change in FEV1 (mL) from baseline to Week 48)	FEV1 is the Forced Expiratory Volume in One Second.	Baseline to Week 48
Secondary	Mean change in FEV1/FVC from baseline to Week 48	FEV1/FVC is the ratio between the Forced Expiratory Volume in One Second and the Forced Vital Capacity.	Baseline to Week 48
Secondary	Time to Progression of BOS	The Progression of BOS is defined as the earliest of the following: Absolute decrease from baseline in FEV1 >/= 10% or >/= 200 mL and absolute decrease in FEV1/FVC of > 5% OR; Change in BOS Severity, OR; Re-transplantation, OR; Death from respiratory failure. This endpoint will be assessed in a combined analysis with a similar Phase III clinical trial, BT - L-CsA - 301 - SLT (BOSTON-1) which will be conducted in the same investigational centers in patients who have undergone single-lung transplantations.	From date of randomization until the date of first documented progression of BOS, or date of retransplantation, or date of death from respiratory failure, whichever came first, assessed up to 52 weeks.